🤰 Preeclampsia Anesthesia Risk Stratification

Endothelial Dysfunction, Vasospasm & Proteinuria

Preeclampsia begins in the placenta, not the maternal vasculature. Failure of normal spiral artery remodeling during the first and second trimesters leaves the placental bed under-perfused and hypoxic. The placenta responds by releasing circulating anti-angiogenic and inflammatory factors that injure endothelium throughout the maternal body — producing the hypertension, proteinuria, and multi-organ dysfunction that define the maternal syndrome.

• 5–8%: Incidence (of all pregnancies worldwide)
• ≥20 wks: Onset (gestation, by definition)
• >38: sFlt-1/PlGF ratio (rule-in cutoff near term)
• ~14%: Global maternal deaths (attributable to hypertensive disorders)

Abnormal placentation — the first hit

In a normal pregnancy, extravillous trophoblast cells invade the maternal spiral arteries during the first and second trimesters, stripping their muscular and elastic walls and converting them into wide, flaccid, low-resistance conduits capable of delivering the 500–700 mL/min of blood flow the term placenta requires. In preeclampsia, this remodeling is shallow and incomplete — trophoblast invasion is largely limited to the decidual segments of the spiral arteries, leaving the myometrial segments narrow, muscular, and reactive to vasoconstrictor stimuli.

The result is a placental bed that is intermittently or chronically under-perfused, producing local hypoxia and oxidative stress. This is the "first hit" of the classic two-stage model of preeclampsia: an abnormal placenta, clinically silent, that sets the stage for the maternal syndrome to follow weeks or months later.

Anti-angiogenic factors — the second hit

The hypoxic placenta releases large quantities of soluble fms-like tyrosine kinase-1 (sFlt-1), a truncated, secreted form of the VEGF receptor, along with soluble endoglin (sEng), a co-receptor for TGF-β. Both circulate in maternal blood and act as biological sponges: sFlt-1 binds and neutralizes circulating VEGF and placental growth factor (PlGF) before they can reach endothelial receptors; sEng impairs TGF-β signaling in the vessel wall.

VEGF and PlGF are constitutively required to maintain fenestrated, nitric-oxide-producing, anti-thrombotic endothelium — particularly in the kidney, liver, and brain. Their sudden systemic withdrawal converts maternal endothelium from a protective, vasodilating surface into an activated, vasoconstricting, pro-thrombotic one. This is why an elevated sFlt-1/PlGF ratio (>38 near term, >85 preterm) has become a validated tool to rule in or rule out preeclampsia in women with suspicious signs.

Placental hypoperfusion drives release of sFlt-1, which scavenges VEGF and PlGF — this systemic antiangiogenic imbalance is now recognized as the central pathophysiologic driver of the maternal syndrome, explaining why delivery of the placenta remains the only definitive cure for preeclampsia.

From endothelial injury to the clinical triad

Systemic endothelial dysfunction produces the clinical hallmarks anesthesiologists must screen for at every encounter:

• Hypertension: loss of endothelial nitric oxide and prostacyclin production, combined with increased sensitivity to angiotensin II, raises systemic vascular resistance and blood pressure.

• Proteinuria: glomerular endotheliosis — swelling and podocyte injury in the glomerular capillary endothelium — increases permeability to protein, producing proteinuria ≥300 mg/24h or a protein:creatinine ratio ≥0.3.

• Vasospasm and end-organ ischemia: cerebral vasospasm underlies headache, visual disturbance, and eclamptic seizures; hepatic vasospasm and microthrombi underlie epigastric pain and HELLP syndrome; uteroplacental vasospasm worsens fetal growth restriction.

• Third-spacing and hemoconcentration: capillary leak from endothelial injury produces edema and reduces effective intravascular volume — relevant to anesthetic fluid management, since these patients are frequently volume-contracted despite visible edema.

Severity Staging — From Preeclampsia to Eclampsia

Preeclampsia is not a single diagnosis but a dynamic spectrum. The same patient can move from "without severe features" to eclamptic seizure within hours, so anesthesiologists must re-stratify severity at every contact — not rely on the label written at admission.

• ≥160/110: Severe-range BP (mmHg, confirmed)
• <100: Severe-feature platelet cutoff (×10³/µL)
• >600: HELLP LDH threshold (U/L, with schistocytes)
• 1:2,000–3,448: Eclampsia incidence (deliveries, developed world)

Preeclampsia without vs. with severe features

Preeclampsia is diagnosed as new-onset hypertension (≥140/90 mmHg on two occasions ≥4 hours apart, after 20 weeks) plus proteinuria or, in its absence, evidence of maternal end-organ dysfunction.

Severe features — any one of which reclassifies the patient — include: systolic BP ≥160 mmHg or diastolic ≥110 mmHg (confirmed on repeat within minutes); platelet count <100,000/µL; serum creatinine >1.1 mg/dL or doubling from baseline; liver transaminases more than twice the upper limit of normal with right-upper-quadrant or epigastric pain; pulmonary edema; or new-onset cerebral/visual disturbance (headache unresponsive to analgesia, scotomata).

Critically, proteinuria alone no longer defines severity — a patient with modest proteinuria but a platelet count of 60,000/µL is a severe-feature patient and an anesthetic priority.

HELLP syndrome

HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets) is a severe variant that can occur with minimal or absent hypertension, making it easy to miss. Diagnostic criteria typically include: microangiopathic hemolysis (schistocytes on smear, LDH >600 U/L, indirect bilirubin elevation, low haptoglobin), AST/ALT more than twice normal, and platelets <100,000/µL (often <50,000/µL in "class 1" disease).

HELLP carries substantial maternal risk: hepatic subcapsular hematoma or rupture, disseminated intravascular coagulation (DIC), placental abruption, and acute kidney injury. Rapidly falling platelets in HELLP can close the neuraxial window within hours, so serial complete blood counts are mandatory once HELLP is suspected.

Eclampsia — the neurologic endpoint

Eclampsia is a new-onset generalized tonic-clonic seizure (or coma) in a woman with preeclampsia, not attributable to another cause. It occurs in roughly 1 in 2,000–3,448 deliveries in resource-rich settings and remains far more common where magnesium prophylaxis and antenatal care are limited. Up to 20–25% of eclamptic seizures occur postpartum, most within the first 48 hours but occasionally later.

Eclampsia is a medical emergency: maintain airway and left uterine displacement, give supplemental oxygen, treat the seizure and prevent recurrence with magnesium sulfate (not benzodiazepines or phenytoin as first line), and control severe hypertension. Once the patient is stabilized, delivery is usually indicated regardless of gestational age.

A patient can transition from "preeclampsia without severe features" to an eclamptic seizure within hours — severity is a spectrum, not a fixed diagnosis, and the anesthesia plan must be reassessed at every encounter, including immediately before performing a neuraxial block.

Platelet Count Thresholds for Neuraxial Anesthesia

Platelet count is the single most important laboratory value gating the decision to place a spinal or epidural block in preeclampsia. It is not a hard cutoff but a probabilistic threshold, weighed together with the platelet trend, any coagulopathy, and the urgency of delivery.

• >100: Generally safe threshold (×10³/µL)
• 70–100: Individualized "gray zone" (×10³/µL)
• <50: Usually avoided below (×10³/µL)
• <1:200,000: Epidural hematoma incidence (obstetric neuraxial blocks)

Why platelet count matters for neuraxial safety

Placing a spinal or epidural needle traverses the epidural venous plexus, a valveless network of vessels that engorges during pregnancy. Adequate platelet number and function allow rapid formation of a hemostatic plug at any vessel injured during needle or catheter passage. When platelets are low — or dysfunctional, as can occur in preeclampsia even at higher absolute counts — an epidural hematoma can form and compress the spinal cord, a rare but catastrophic complication that can cause permanent paraplegia if not decompressed within hours.

Current society guidance (ASRA/ESAIC/SOAP consensus statements) frames neuraxial platelet thresholds as risk-stratified rather than absolute: >100,000/µL is generally considered safe; 70,000–100,000/µL requires individualized assessment of trend, etiology, and any coagulopathy; below 50,000/µL neuraxial techniques are usually avoided outside of exceptional circumstances.

Trend matters as much as the absolute number

A single platelet count is a snapshot; preeclampsia and HELLP are dynamic processes. A count of 90,000/µL that has been stable for 24 hours carries a different risk profile than 90,000/µL that fell from 220,000/µL over the same period — the latter suggests active consumption (microangiopathy, early DIC) that may continue to fall during or shortly after block placement.

Practical approach: obtain a platelet count within 6 hours of a planned neuraxial procedure in a patient with preeclampsia with severe features or HELLP, and repeat sooner if the trend is rapidly declining or if severe features are worsening. A thromboelastogram (TEG/ROTEM) or point-of-care viscoelastic assay can add functional information beyond the platelet number alone, particularly in the 50,000–100,000/µL gray zone.

The absolute platelet threshold matters less than the trend: a count falling rapidly from 180,000 to 90,000/µL over 12 hours carries more anesthetic risk than a stable count of 80,000/µL, because coagulation function may already be lagging behind the platelet number.

Practical windows of opportunity

Because platelet counts in preeclampsia typically decline over hours to days, early epidural placement in a laboring patient with adequate platelets is a common strategy — it secures a functioning neuraxial catheter that can later be extended for cesarean delivery even if platelets subsequently fall, avoiding a second needle pass at a lower count.

Conversely, if platelets are already borderline (70,000–100,000/µL) and trending down, waiting for "more data" can close the window entirely. Multidisciplinary discussion between obstetrics, anesthesiology, and sometimes hematology should happen early, before an urgent cesarean forces a decision under time pressure.

Magnesium Sulfate — Dosing & Toxicity Monitoring

Magnesium sulfate is the standard of care for seizure prophylaxis in preeclampsia with severe features and for both treatment and secondary prevention of eclampsia. It is a narrow-therapeutic-index drug, so anesthesiologists must know its dosing and its toxicity signs as well as any drug in the obstetric formulary.

• 4–6 g: Loading dose (IV over 15–20 min)
• 1–2 g/h: Maintenance infusion (IV, continuous)
• 4–8 mg/dL: Therapeutic serum level ((≈3.3–6.6 mEq/L))
• ~10 mg/dL: Loss of patellar reflex (earliest toxicity sign)

Mechanism and dosing protocol

Magnesium acts as a physiologic calcium antagonist: it blocks NMDA-receptor calcium channels in the cerebral cortex (raising the seizure threshold), reduces presynaptic acetylcholine release at the neuromuscular junction, and causes vascular smooth muscle relaxation via competition with calcium at voltage-gated channels — producing mild vasodilation, though it is not used as a primary antihypertensive.

Standard regimen: a loading dose of 4–6 g IV administered over 15–20 minutes, followed by a maintenance infusion of 1–2 g/hour continued through labor, cesarean delivery, and for 24 hours postpartum (or 24 hours after the last seizure in eclampsia). In eclamptic seizure recurrence, an additional 2 g IV bolus may be given. Renal impairment (elevated creatinine, oliguria) mandates dose reduction and closer monitoring, since magnesium is renally excreted and toxicity develops faster when clearance is reduced.

Clinical toxicity monitoring

Because therapeutic and toxic magnesium levels are close together, bedside clinical monitoring — not just serum levels — is the mainstay of safety surveillance, performed hourly:

• Deep tendon reflexes (patellar): the earliest sign of rising magnesium, typically lost around 10 mg/dL, before respiratory compromise occurs. Absent reflexes are a signal to hold the infusion and check a level.

• Respiratory rate: should remain ≥12 breaths/min; respiratory depression typically appears around 12–15 mg/dL.

• Urine output: should remain ≥25–30 mL/h, since reduced renal clearance allows magnesium to accumulate; oliguria is both a toxicity risk factor and a sign of reduced clearance.

• Cardiac effects: ECG changes (PR and QRS prolongation) can appear at higher levels, with cardiac arrest reported above roughly 25 mg/dL.

Calcium gluconate (1 g IV, i.e., 10 mL of 10% solution, over 3 minutes) is the antidote for magnesium toxicity and should be immediately available at the bedside whenever an infusion is running.

Magnesium sulfate reduces the risk of eclamptic seizure by roughly 50% compared with placebo (MAGPIE trial) and is superior to phenytoin and diazepam for prophylaxis and treatment of eclampsia — yet it is not an antihypertensive, and it should generally be continued, not stopped, through neuraxial placement and delivery.

Anesthetic interactions

Magnesium potentiates both depolarizing and non-depolarizing neuromuscular blocking agents, prolonging their effect — doses of rocuronium or vecuronium should be reduced and neuromuscular monitoring used if general anesthesia is required in a patient on a magnesium infusion. It also potentiates the hypotensive effects of neuraxial sympathectomy and of other antihypertensives, particularly nifedipine, where the combination can produce profound hypotension and neuromuscular weakness — a recognized synergistic interaction that warrants cautious, incremental dosing of both agents together.

Magnesium does not need to be discontinued for neuraxial placement in a patient with an acceptable platelet count; ongoing infusion is not itself a contraindication to spinal or epidural anesthesia.

Neuraxial vs. General Anesthesia

The choice between neuraxial and general anesthesia in preeclampsia is rarely about maternal preference alone — it is a structured risk trade-off between the coagulation risk of a neuraxial block and the airway and hemodynamic risks of general anesthesia, reassessed for every case.

• Neuraxial: Preferred when platelets allow (spinal, epidural, or CSE)
• ~1:224–390: Obstetric failed-airway rate (vs ~1:2,000 general surgical)
• 20–30: SBP rise with laryngoscopy (mmHg, unblunted)
• ICH: Preeclampsia-related death, leading cause (intracranial hemorrhage)

Why neuraxial anesthesia is preferred

When platelets and coagulation status allow it, spinal, epidural, or combined spinal-epidural (CSE) anesthesia is preferred for both labor analgesia and cesarean delivery in preeclampsia. Neuraxial techniques avoid airway instrumentation entirely — critical in a population with a substantially elevated risk of difficult or failed intubation — and avoid the sharp sympathetic surge that laryngoscopy produces.

Historical concerns that spinal anesthesia causes more severe hypotension than epidural in preeclampsia have been largely refuted by modern data: preeclamptic patients, with their heightened vascular reactivity, often experience less hemodynamic swing with spinal anesthesia than healthy parturients, provided phenylephrine and judicious fluid administration are used proactively.

The airway and hemodynamic risks of general anesthesia

When general anesthesia is required — coagulopathy, platelets too low for neuraxial block, active hemorrhage, eclampsia with an unprotected airway, or a category-1 emergency with no time for a block — two dangers compound each other:

• Airway edema: capillary leak from endothelial injury, combined with the physiologic airway edema of pregnancy, can narrow the glottic opening and friable mucosa; a smaller endotracheal tube and immediate availability of video laryngoscopy and a difficult-airway cart are standard precautions.

• Hypertensive response to laryngoscopy: direct laryngoscopy and intubation trigger a sympathetic surge that can raise systolic pressure by 20–30 mmHg and precipitate pulmonary edema or, most seriously, intracranial hemorrhage — the leading cause of maternal death in preeclampsia. This response must be actively blunted, not merely observed.

Blunting strategies include a short-acting opioid (e.g., remifentanil 1 mcg/kg or fentanyl) or IV labetalol/esmolol immediately before induction, together with a rapid, gentle laryngoscopy technique and, where feasible, video laryngoscopy to shorten instrumentation time.

General anesthesia in severe preeclampsia combines two dangerous elements simultaneously — an airway narrowed by pharyngolaryngeal edema and a sympathetic surge from laryngoscopy that can spike systolic pressure by 20–30 mmHg, a level implicated in maternal intracranial hemorrhage, the leading cause of preeclampsia-related death.

Anesthetic technique options in preeclampsia

Antihypertensive Titration

Severe hypertension (≥160/110 mmHg, confirmed) in preeclampsia is a treat-urgently situation — it must be controlled within roughly 30–60 minutes to reduce the risk of maternal stroke — but the target is deliberate under-correction, not normalization, to protect uteroplacental perfusion.

• 140–150: Target SBP after treatment (mmHg (not lower))
• 90–100: Target DBP after treatment (mmHg (not lower))
• 300 mg: Labetalol IV max cumulative (per episode)
• 50 mg/h: Nifedipine PO max (immediate-release)

Why conservative targets, not normal blood pressure

In preeclampsia, uteroplacental perfusion already runs on a pressure-dependent, narrowly autoregulated system distal to the diseased spiral arteries. Aggressive normalization of maternal blood pressure can drop perfusion pressure below what the placenta needs, producing acute fetal compromise even as the maternal number looks reassuring.

Guideline-consistent practice therefore treats severe-range hypertension (≥160/110 mmHg) urgently, but aims only to bring pressure into a safer range — roughly systolic 140–150 mmHg and diastolic 90–100 mmHg — rather than to a "normal" 120/80 mmHg. Overshoot is treated the same way overshoot with any titrated vasoactive drug is treated: slow down, reassess, and give the next dose only after allowing time for the previous one to take full effect.

First-line agents and titration protocol

Three agents dominate first-line therapy for acute severe hypertension in pregnancy, each titrated on a fixed interval rather than pushed rapidly:

• IV labetalol: 20 mg IV, then doubling to 40 mg, then 80 mg, then 80 mg again every 10 minutes as needed, to a cumulative maximum around 300 mg. Combined alpha-1/beta blockade lowers pressure without the reflex tachycardia hydralazine can cause; avoid in asthma, bradycardia, or high-grade heart block.

• IV hydralazine: 5–10 mg IV every 20 minutes as needed. Direct arteriolar vasodilation, longer and less predictable duration of action, and a tendency to reflex tachycardia and occasional overshoot hypotension.

• Oral immediate-release nifedipine: 10–20 mg PO, may repeat in 30 minutes, to a maximum of roughly 50 mg over the first hour. Useful when IV access or agents are delayed; avoid sublingual administration due to unpredictable, rapid absorption.

All three are considered comparably effective first-line choices by major society guidelines; selection is usually driven by available access, comorbidities, and local familiarity.

Special interactions and second-line therapy

Nifedipine and magnesium sulfate act synergistically on vascular and neuromuscular calcium channels — co-administration can produce profound hypotension and unexpectedly deep neuromuscular weakness, so incremental dosing and close monitoring are warranted whenever both are running.

When first-line agents fail to achieve control, second-line continuous infusions (nicardipine or, rarely, sodium nitroprusside) are used in a monitored/critical-care setting, typically with arterial line blood pressure monitoring given their potency and rapid onset. Methyldopa, by contrast, is used for chronic, non-urgent blood pressure control in pregnancy but is far too slow in onset for acute severe hypertension.

The goal of antihypertensive therapy in severe preeclampsia is safety, not normalization: lowering pressure too far or too fast can compromise uteroplacental perfusion that is already reduced by vasospasm, so the conservative target ranges (SBP 140–150, DBP 90–100 mmHg) are a deliberate clinical choice, not an undertreatment.

First-line antihypertensives for severe hypertension in pregnancy